Ninlaro Failure Leaves Little In AL Amyloidosis Pipeline

 
• By Ian Haydock

Takeda proteasome inhibitor stumbles at Phase III among potential first therapies for a deadly form of amyloidosis.

Multiple Myeloma Awareness: Bone marrow aspirate cytology of multiple myeloma, a type of bone marrow cancer of malignant plasma cells, associated with bone pain, bone fractures and anemia.
Phase III Amyloidosis Failure for Ninlaro • Source: Shutterstock

More from Clinical Trials

More from R&D